|
Clinical characteristic
|
Pre-COVID phase
|
COVID phase
|
p value
|
|---|
|
Patient (n)
|
614
|
600
| |
|
Age (in years) + SD
|
55.27 ± 17.09
|
56.97 ± 15.09
|
0.56
|
|
Sex (M/F)
|
402/212
|
378/222
|
0.37
|
|
Rural (n, %)
|
387 (63.03)
|
398 (66.34)
|
0.23
|
|
Urban (n, %)
|
227 (36.97)
|
202 (33.67)
|
|
HTN (n, %)
|
238 (38.76)
|
218 (36.33)
|
0.40
|
|
Diabetes (n, %)
|
213 (34.6)
|
189 (31.5)
|
0.24
|
|
CKD (n,%)
|
73 (11.88)
|
54 (9)
|
0.11
|
|
CAD (n, %)
|
205 (33.38)
|
189 (31.5)
|
0.50
|
|
Indication of OAC
|
|
Atrial fibrillation (n, %)
|
156 (25.4)
|
174 (29)
|
0.17
|
|
Prosthetic valve (n, %)
|
254 (41.3)
|
232 (38.7)
|
0.34
|
|
Pulmonary thromboembolism (n, %)
|
117 (19.1)
|
101 (16.9)
|
0.33
|
|
Other (n, %)
|
87 (14.16)
|
93 (15.5)
|
0.46
|
|
Drugs
|
|
OAC (n, %)
|
525 (86.6)
|
506 (84.4)
|
0.57
|
|
NOAC (n, %)
|
89 (14.4)
|
94 (15.6)
|
0.57
|
|
Antiplatelets (n, %)
|
267 (43.48)
|
218 (36.33)
|
0.01
|
- OAC oral anticoagulants-warfarin and nicoumalone, HTN hypertension, CKD chronic kidney disease, CAD coronary artery disease
